Trade Pliant Therapeutics, Inc. - PLRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.96 |
| Open | 3.06 |
| 1-Year Change | -80.3% |
| Day's Range | 2.97 - 3.08 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 3.04 | 0.04 | 1.33% | 3.00 | 3.08 | 2.96 |
| Feb 20, 2025 | 2.96 | 0.02 | 0.68% | 2.94 | 3.11 | 2.88 |
| Feb 19, 2025 | 2.96 | 0.00 | 0.00% | 2.96 | 3.06 | 2.90 |
| Feb 18, 2025 | 2.94 | -0.09 | -2.97% | 3.03 | 3.16 | 2.88 |
| Feb 14, 2025 | 2.99 | -0.14 | -4.47% | 3.13 | 3.43 | 2.95 |
| Feb 13, 2025 | 3.25 | 0.22 | 7.26% | 3.03 | 3.73 | 3.03 |
| Feb 12, 2025 | 2.67 | 0.15 | 5.95% | 2.52 | 2.69 | 2.40 |
| Feb 11, 2025 | 2.56 | -0.43 | -14.38% | 2.99 | 3.00 | 2.56 |
| Feb 10, 2025 | 3.02 | 0.24 | 8.63% | 2.78 | 3.38 | 2.78 |
| Feb 7, 2025 | 7.74 | -4.04 | -34.30% | 11.78 | 11.78 | 7.14 |
| Feb 6, 2025 | 11.92 | -0.38 | -3.09% | 12.30 | 12.68 | 11.87 |
| Feb 5, 2025 | 12.51 | 1.22 | 10.81% | 11.29 | 12.77 | 11.17 |
| Feb 4, 2025 | 11.34 | 0.27 | 2.44% | 11.07 | 11.42 | 10.88 |
| Feb 3, 2025 | 11.14 | 0.71 | 6.81% | 10.43 | 11.17 | 10.26 |
| Jan 31, 2025 | 10.69 | 0.07 | 0.66% | 10.62 | 11.00 | 10.47 |
| Jan 30, 2025 | 10.61 | -0.22 | -2.03% | 10.83 | 11.02 | 10.58 |
| Jan 29, 2025 | 10.69 | -0.09 | -0.83% | 10.78 | 10.98 | 10.67 |
| Jan 28, 2025 | 10.88 | 0.01 | 0.09% | 10.87 | 11.02 | 10.69 |
| Jan 27, 2025 | 10.95 | 0.05 | 0.46% | 10.90 | 11.25 | 10.81 |
| Jan 24, 2025 | 10.86 | -0.16 | -1.45% | 11.02 | 11.16 | 10.77 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Pliant Therapeutics, Inc. Company profile
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Pliant Therapeutics Inc revenues decreased 82% to $7.6M. Net loss increased from $41.5M to $97.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 14% to $73.6M (expense), General and administrative - Balancing increase of 39% to $21M (expense).
| Industry: | Pharmaceuticals (NEC) |
260 Littlefield Avenue
Suite 150
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com